Didanosine has shown activity against the human immunodeficiency virus (HIV) in both children and adults. We prospectively assessed T-helper cell (Th) function as determined by in vitro interleukin-2 (IL-2) production in response to a panel of T-cell stimuli in 22 HIV-infected children before and during didanosine therapy and we correlated the incidence of opportunistic and recurrent bacterial infections with changes in p24 antigen and CD4 counts. Didanosine (270, 360, or 540 mg/m2/d) was administered orally for periods ranging from 8 to 40 weeks (mean, 24 weeks). Five of six asymptomatic patients (Centers for Disease Control P-I) compared with 6 of 16 symptomatic (P-2) patients exhibited improved Th func-ATIENTS INFECTED with human immunodeficiency P virus (HIV) exhibit a time-dependent reduction in CD4+ T-helper cells (Th), become susceptible to opportunistic infections, and ultimately develop the acquired immunodeficiency syndrome (AIDS).' The same pattern of progression to AIDS appears to be even more accelerated in vertically infected infants and ~h i l d r e n .~,~ Several investigators have reported that defects in Th function can occur without a significant reduction in CD4 counts in asymptomatic adult patient^.^-^ Furthermore, a progressive series of defects measured by in vitro T-cell stimulation can be detected that are initially manifested by selective loss of Th to recall antigens, such as influenza A virus (FLU) and tetanus toxoid (TET), without a concomitant loss in T-cell activity to HLA alloantigens (ALLO) or to the mitogen phytohemagglutinin (PHA).s This initial defect is followed by the loss of Th function to ALLO and finally to PHA as well. We have recently reported a similar spectrum of T-cell unresponsiveness in pediatric patients with HIV infe~tion.~ Dideoxynucleosides such as z i d~v u d i n e~~-'~ and, more recently, didan~sine'~-'~ have been shown to have demonstrable antiretroviral activity in the treatment of HIVinfected patients. The immunologic parameter most frequently used to monitor these protocols has been the number of CD4+ cells. However, monitoring the number of CD4+ cells alone may not provide a complete profile for assessing the immunologic responsiveness of HIV-infected 
tion (greater than threefold increase in IL-2 production to at least 2 of the 4 stimuli) during therapy. Of 12 patients without infections during therapy, 9 (75%) showed improvement in Th function, compared with only 2 of 10 patients with infections (P = .03). Notably, the incidence of infections was not correlated with improvements in CD4 count or decreases in p24 antigen. Improvement in Th function during didanosine therapy is correlated with decreased incidence of infections. Assessment of Th function may provide an additional measurement of immunologic response to antiretroviral therapy. This is a US government work. There are no restrictions on its use.
patients to antiretroviral therapy. In this report, we present data on changes in Th function during didanosine therapy in pediatric HIV-infected patients. The in vitro responses to stimulation with FLU, TET, L L O , and PHA are compared with the clinical status of the patients as assessed by the number of opportunistic and bacterial infections observed during therapy.
PATIENTS AND METHODS
Patients. Twenty-two children infected with HIV and enrolled in a phase 1-11 trial of didanosine coordinated by the Pediatric Branch, National Cancer Institute,I7 were studied. All patients met the criteria established by the Centers for Disease Control (CDC) for the case definition of HIV infection in infants and children.'* Six of the 22 children were asymptomatic or very mildly symptomatic but had CD4 counts less than 500/kL (CDC class P-lB). The remaining patients were moderately or severely symptomatic (CDC class P-2B, D, or F). Although eight P-2 patients had received zidovudine in the past, none had received antiretroviral agents during the 4 weeks before the evaluation of the baseline Th function. Eighteen patients were receiving Pneumocystis prophylaxis with either trimethoprimlsulfamethoxazole or aerosolized pentamidine.
Twenty HIV-negative healthy adult blood donors, as well as 15 children (aged 19 months to 14 years), admitted to The Children's National Medical Center (Washington, DC) for minor surgical procedures served as controls. Informed consent was given by the parents or legal guardian of the patients and control children. The study was performed with the approval of the Institutional Review Boards of the medical centers.
In vitro interleukin-2 (IL-2) production. Mononuclear cells (PBMC) were separated from heparinized venous blood by Ficoll density centrifugation. The separated PBMC were washed twice in phosphate-buffered saline, counted by trypan blue exclusion, and resuspended at 3 x 106/mL in RPMI 1640 (GIBCO, Grand Island, NY) containing 0.5% penicillin and 1% glutamine.
Cells were cultured in 96-well flat-bottom Linbro tissue culture plates (Costar, Cambridge, MA) at a concentration 3 x lo5 per well with or without in vitro stimulation. The stimuli used were (1) FLU (AIHong Kong RX73, H3N2) at a final dilution 1:500; (2) TET at a final dilution of 40 IfImL (Massachusetts Department of Health, Boston, MA); (3) a pool of irradiated (5,000 rad) PBMC from two or more unrelated HIV-negative donors (2 x 105 cells per well); and (4) PHA (GIBCO) at a final concentration of l:100.8,9 After 7 days of incubation at 37"C, supernatants were collected and stored at -20°C.
The activity of IL-2 in culture supernatants was assayed by its ability to support proliferation (determined by 3H-thymidine incorporation) of the IL-2-dependent cytotoxic T-lymphocyte line (CTLL), as described previo~sly.~*~ Results are expressed as mean counts per minute (cpm) for 3 replicate wells for a given supernatant dilution.
Subjects were defined as responders to a given antigen if the mean cpm of their stimulated cultures was greater than 3 SD above the mean cpm of unstimulated cultures of control subjects. The cutoff value for IL-2 production was derived from 15 control children and was 7,100 cpm. Relative units of IL-2 were calculated as the supernatant dilution corresponding to half-maximal CTLL proliferation. This dilution was, in turn, computed by extrapolation of the line generated by applying linear regression analysis (least squares method) to the cpm of CTLL proliferation (y values) as a function of the supernatant dilution, and using off-plateau values.
The Th function as well as CD4 counts, CD8 counts, and p24 antigen were prospectively evaluated before therapy, and again during treatment within periods ranging from 8 to 40 weeks (median, 24 weeks). The patients were monitored for development of infections from the initiation of therapy until the end of the study. The clinical observation period extended for a median of 12 weeks after the second test of Th function and for a median of 40.5 weeks from the initiation of didanosine therapy.
Improvement in Th function for a particular stimulus was defined as an increase of greater than threefold in IL-2 units from the baseline (pretherapy) sample to the follow-up (during therapy) sample for a given patient. An increase of threefold or greater in T-cell function has been used as indicator of immunologic improvement in another study of adult patients on didanosine therapy. I5 We considered baseline values of 1 U for FLU and TET, 8.3 U for ALLO, and 10 U for PHA to be threshold values, such that patients exhibiting these baseline values were not considered to be Th functionally deficient. The 8.3 U for ALLO and 10 U for PHA were selected based on mean values obtained from 15 control children.
The patients were observed for opportunistic infections (01s) and recurrent bacterial infections (BIs) throughout the clinical observation period. Patients were classified as being free from infections if they had no 01s or no more than one BI. Patients were classified as having had infections if they encountered at least one 0 1 and/or more than a single BI during that period. 01s were considered as those required for the CDC P-2D classification of children with HIV infection'* and included either persistent orophalyngeal or esophageal candidiasis, Pneumocystis carinii pneumonia, diarrhea due to cryptosporidia, atypical mycobacterial infection, cytomegalovirus (CMV) infection, severe herpetic stomatitis, and recurrent or persistent varicella-zoster infection. The BIs were either microbiologically documented or clinically defined. Focal infections (sinusitis and pneumonia) as well as systemic infections (septicemia) were considered in this definition. However, catheter-related infections were excluded from the evaluation of the patients. The history of infections was then correlated with the Th functional studies of the patients that had been independently performed by two of the investigators (M.C. and G.M.S.).
The Fisher's exact test was used for comparisons of proportions between two groups. The exact distribution of the Wilcoxon rank sum test was used to compare the numbers of tests on which Th function improved. Cross-validation of the standard logistic regression model19 was conducted by a sequential leave-out-one procedure.20 All P values reported are two-tailed.
Study design and evaluation ofpatients.

Statisticalanalysis
RESULTS
Demographics and laboratory values before and during
The CD4 and CD8 counts, the serum levels of therapy.
p24 antigen, and the serum IgG levels of the six P-1 (including 3 marginally symptomatic children) and 16 P-2 patients before and during therapy are shown in Table 1 (Fig 1) . Figure 1A and B show a representative patient's PBMC with low responses to all four stimuli before therapy (Fig lA) There was a greater probability of patients at earlier stages of disease to show improvement of Th function in response to therapy. As shown in Table 3 , when patients were categorized according to the number of T h functional tests that improved on therapy, higher proportions of Th responses improved among P-1 patients compared with P-2 patients (by Wilcoxon test, P = .026). Furthermore, because some patients exhibited a high pretherapy Th function to one o r more stimuli (usually to ALLO and PHA), we compared the number of P-1 and P-2 patients who exhibited an improvement of those T h responses that were low before therapy. The comparison shows that P-1 patients showed a greater probability to improve their Th responses (by Wilcoxon test, P = .016). In fact, there was only one P-1 patient who exhibited improvement in T h response to only one of three stimuli with a low baseline. In the remaining five P-1 patients, more than 50% of the Th responses that Changes of Th function during therapy.
21).
For personal use only. were initially low showed improvement. These proportions differ from those observed among the 16 P-2 patients, of whom only 6 showed a comparable (more than 50%) improvement in Th responses. This different pattern of improvement was observed despite the fact that the P-1 patients did not start therapy with baseline Th responses significantly higher than those of the P-2 group. There was no correlation between changes in Th function and age of the patients or route of acquisition of HIV (vertically acquired versus transfusion-acquired virus). In addition, the CD4 and CD8 counts, as well as the p24 antigen of the patients who experienced improvement in more than 50% of their Th responses, did not differ from those values of the patients who did not show Th improvement.
Th function and surrogate markers of disease in patients with or without infections. Twelve of 22 patients were classified as having been free of infections during the clinical observation period. In contrast, the remaining 10 patients had multiple episodes of 01s and/or BIs and were classified as having been with infections. There was no significant difference in the pretherapy history of infections between the six P-2 patients who remained free of infections and the 10 P-2 patients who had infections during therapy. Among the individuals free of infections (patients 1 through 12), 1 (patient 7) showed no improvement at all, 2 (patients 2 and 12) showed improvement in one of three initially low Th responses, 5 (patients 1, 5, and 8 through 10) in two of four stimuli, and 4 (patients 3,4,6, and 11) in all initially low responses. In contrast, among 10 patients with infections (patients 13 through 22), 3 (patients 17, 19, and 22) did not show any improvement, 5 (patients 14 through 16,18, and 21) showed improvement in response to only one of four stimuli, 1 (patient 20) improved in response to one of two initially low responses, and 1 (patient 13) in response to two of three initially low responses. The difference between the two groups was significant by Wilcoxon test (P = .0063; data from Table 2 ).
There were no significant differences in the proportions of patients with increases of CD4 and CD8 counts ( Table  4) . Furthermore, all patients who started therapy with detectable levels of p24 antigen showed a decrease during therapy, independent of whether they had infections. In contrast, there was a significant correlation between improvement of Th responses and a follow-up period without infections (P = .03).
Logistic regression applied to the data contained in Table 2 correctly classified 11 of 12 patients free of infections and 9 of 10 patients with infections. The crossvalidation procedure has given classification proportions of 9 of 12 and 8 of 10 (by Fisher's exact test, P = .076). PHA appears to be the most significant variable in the logistic regression, although ALL0 is also significant. FLU and TET are not significant, but appear to contribute to better classification in the cross-validation procedure.
Because a lack of improvement in Th function was shown to correlate with higher incidence of infections during the clinical observation period in these patients, it was imporFor personal use only. on October 23, 2017. by guest www.bloodjournal.org From 
The first number is the baseline value and the second number is the follow-up value of IL-2 units.
tant to review the infections. Twenty-six episodes of 01s and 18 episodes of BIs occurred in the group with infections compared with no 01s and only six episodes of BIs in the group free of infections. The patients who exhibited more than 50% improvement of pretherapy Th function (11 patients) had a period of clinical observation equal to that of those who did not exhibit a 50% improvement (11 patients) (37.2 2 10.5 weeks v 37.0 2 13.0weeks, respectively). Three episodes of oropharyngeal candidiasis and two episodes of herpetic stomatitis recurred in a single patient among those who exhibited improvement of more than 50% of the Th responses that were initially low. In contrast, the infections that occurred in the group of patients with less than 50% improvement included 16 cases of Candida albicans infections (14 episodes of oropharyngeal and 2 episodes of esophageal candidiasis), one case of CMV retinitis, three cases of multidermatomal or recurrent herpes-zoster, and one case of severe herpetic stomatitis. The vast majority of the 24 BIs were clinically diagnosed or microbiologically proven respiratory tract infections requiring recurrent courses of antibiotics.
DISCUSSION
Antiretroviral therapy has been associated with clinical improvement and improvement in surrogate markers of infection, especially increases in CD4 counts and decreases in p24 antigen. However, it has not been established whether these changes correlate with a decreased incidence of infections. Moreover, a lack of correlation between CD4 count and Th function has been reported in HIV-positive asymptomatic adults8 and children with or without symptoms of AIDS.9 Thus, it is important to determine whether antiretroviral therapy improves Th function and whether this correlates with a reduction in infections. Recognizing the limitations of our sample size and the length of follow-up, we found that (1) Th function improved in some but not all patients; (2) further deterioration of Th function did not occur; (3) improved Th function appeared to be limited to increases in responses to ALLO and PHA, but not to recall antigens; (4) improvement in Th function was seen more consistently in patients at earlier stages of the disease; (5) no correlation between improvement in Th function and increase in CD4 count or decrease in p24 antigen was observed; and (6) most importantly, the improvement in Th function was associated with a lower incidence of infections.
Immune functional parameters have been evaluated in adult patients receiving either zidovudine or d i d a n o~i n e .~~J~,~~ In one study, 5 of 17 patients receiving didanosine developed delayed-type hypersensitivity and 5, 2, and 3 of 9 patients, respectively, responded by proliferation to pokeweed mitogen, TET, and diphtheria t0x0id.l~ Our results resemble these proliferative responses in that improvement of in vitro T-cell responses to recall antigens were more difficult to observe than improvement in responses to mitogens or alloantigens. In two other studies, in vitro stimulation of T lymphocytes with anti-CD3 monoclonal antibody or with PHA has been used as indicator of the efficacy of antiretroviral therapy with zidovudine.21,22 However, our study differs from the reports on zidovu- in that we were able to detect improved Th function for a longer time period.
The findings of our study also suggest that assessment of Th function may be an important addition to the list of surrogate markers for the assessment of antiretroviral therapies. Monitoring the CD4 count has been used as a marker of immune function in HIV-infected individuals, and patients who have severely reduced CD4 counts are considered to be functionally immune-deficient.' Nevertheless, it has been established that Th dysfunction can occur years before a critical reduction in CD4+ cell numbers and/or the appearance of other AIDS-related symptom^.^,^ Immune responses to recall antigens, especially those of infectious agents, might be useful indicators of the immune system's potential to resist infection, especially during the early period of HIV infection. For this reason, we considered the in vitro responses to FLU and TET for evaluating drug-induced changes in Th function that would reflect clinical improvement. However, we observed in both P-1 and P-2 pediatric patients that didanosine did not result in improvement of Th function that could be measured by in vitro IL-2 production in response to FLU and E T . In contrast, improvement in Th function assessed by IL-2 responses to ALLO and PHA was observed in 80% of the P-1 children and in a lower proportion of P-2 patients. Furthermore, logistic regression analysis suggested that the response to PHA correlated slightly better with clinical status than the response to ALLO. We have recently reported a correlation between loss of responsiveness of PBMC to recall antigens and increased susceptibility to bacterial infections, whereas the loss of response to PHA was associated with increased susceptibility to OIs? Consistent with these observations is our current finding that the improvement of the PHA-stimulated Th response, as measured by IL-2 production, is correlated with lower frequency of 01s. As in other s t~d i e s , '~-'~ we observed increases in CD4 counts and/or CD4/CD8 ratios in the majority of the children on didanosine, and a reduction in p24 antigen in all of the patients who started with detectable levels of p24 antigen. However, the reduction in infections did not correlate well with either increased CD4 count or decreased p24 antigen during therapy. Thus, it appears that Th responses to PHA and to ALLO might be a more sensitive marker, because they correlate with a reduction in BIs and 01s. A similar increase in Th function has been For personal use only. on October 23, 2017. by guest www.bloodjournal.org From recently obtained in adult patients on zidovudine therapy.23 Th function may be the "X factor" recently postulated to account for the lack of correlation between CD4 counts and clinical status in patients receiving antiretroviral therapy. 24 It is important to note that HIV-infected children not receiving antiretroviral therapy were not studied as controls, nor would it be ethical to do so. However, it is notable that, among 80 asymptomatic HIV-infected adults who were not on antiretroviral therapy and were retested for Th function over a 12-to 15-month interval, only 4 individuals showed any i m p r o~e m e n t .~,~~ It is unlikely, therefore, that the Th improvement observed in this study would have occurred without therapy.
The reason(s) for the improvement of Th responses to ALLO and PHA, but not to FLU and TET, is not known. One possibility could be the fact that in healthy individuals, Th responses to FLU and TET are often weaker than the responses to ALLO and PHA,25 perhaps due to differences in the frequency of Th precursors. Thus, HIV-induced deterioration of immune function may be more severe for weaker responses and these responses may be more difficult to restore by therapy. Another possibility is that T cells expressing memory marker phenotypes are selectively depleted in AIDS patients,26sZ7 which could preferentially affect Th responses to recall antigens. It is also possible that the pool of memory T cells did not have the opportunity to have expanded in children as much as in adults, and that restoration of Th function to recall antigens would therefore be more difficult. A fourth possibility is that these patients exhibit not only a Th defect, but also a deficiency in antigen presenting cell (APC) function. Using in vitro tests similar to those used here, defects in APC function have been observed in approximately 50% of adult AIDS patients,28 but not in asymptomatic HIV-infected individua l~.~~ Furthermore, it has been shown that Th responses by human PBMC to FLU and TET are much more dependent on functionally intact autologous APC than the responses to ALLO and PHAZ5 If these patients exhibit defects in both Th and APC function, it is possible that didanosine therapy improved Th but not APC function. Therefore, it may be important to include assays for both APC and Th function in evaluating the efficacy of antiretroviral therapy on the immune function of patients.
In summary, the data presented here suggest that improvements in Th function appear to be associated with a reduction of 01s or recurrent BIs. Because such laboratoryclinical improvements can be obtained with antiretroviral therapy, these data suggest that serial assessment of Th function might be a sensitive marker for assessing the activity of antiretroviral therapy on the immune system and that it deserves further consideration as an adjunct to measuring the CD4 count.
